Can a 65-year-old patient with normal liver function, an intact gallbladder, and no excessive alcohol use take VIBERZI (eluxadoline) for irritable bowel syndrome with diarrhea?

Can Elderly Patients Take VIBERZI (Eluxadoline)?

Yes, a 65-year-old patient with normal liver function, an intact gallbladder, and no excessive alcohol use can take VIBERZI, but they should receive the lower 75 mg dose twice daily and be monitored more closely for adverse events.

Key Considerations for Elderly Patients

Efficacy in Older Adults

The drug remains effective in elderly patients. No overall differences in effectiveness were observed between patients ≥65 years and younger patients 1. However, clinical trial data from the phase 3 studies showed that among elderly patients specifically, a greater proportion achieved composite response, abdominal pain relief, and stool consistency improvement with the 75 mg dose compared to the 100 mg dose 2.

Safety Profile in the Elderly

While VIBERZI can be used in elderly patients, they experience a higher rate of adverse events compared to younger patients 1:

• Overall adverse events: 66% vs 59% in younger patients
• Serious adverse events: 9% vs 4% in younger patients
• Gastrointestinal adverse events: 39% vs 28% in younger patients

The most common adverse events remain constipation (8%), nausea (7%), and abdominal pain (7%) 3.

Dosing Recommendation

For your 65-year-old patient, start with 75 mg twice daily with food 3. This lower dose is supported by:

1. Better response rates in elderly patients at 75 mg vs 100 mg 2
2. Lower risk of adverse events
3. Current guideline recommendations for dose reduction in specific populations

Absolute Contraindications to Verify

Before prescribing, confirm your patient does NOT have 3, 1:

• Absence of gallbladder (cholecystectomy) - ABSOLUTE CONTRAINDICATION
• Excessive alcohol use (>3 drinks/day) - ABSOLUTE CONTRAINDICATION
• History of pancreatitis or pancreatic problems
• History of sphincter of Oddi dysfunction
• Severe liver impairment (your patient has normal liver function, so this is satisfied)
• Chronic or severe constipation
• Bowel obstruction history

Critical Safety Monitoring

Pancreatitis and Sphincter of Oddi Spasm Risk

The most serious adverse events are pancreatitis (0.3-0.5% incidence) and sphincter of Oddi spasm, which occur primarily in patients without a gallbladder 3, 4. Since your patient has an intact gallbladder, this risk is substantially lower. These events typically occur within the first week of treatment, often after just 1-2 doses 1, 5.

Instruct the patient to STOP the medication immediately and seek emergency care if they develop 1:

• New or worsening abdominal pain
• Upper right abdominal pain radiating to back or shoulder
• Pain with or without nausea/vomiting

Additional Monitoring

Given the higher adverse event rate in elderly patients, monitor for 1:

• Severe constipation (discontinue if this develops)
• Mental or physical impairment affecting driving or operating machinery
• Signs of allergic reaction (rare but can occur after 1-2 doses)

Guideline Support

Both the 2022 AGA guidelines and 2021 British Society of Gastroenterology guidelines support eluxadoline use in IBS-D 3, 6. The AGA provides a conditional recommendation with moderate certainty evidence, noting that eluxadoline is particularly effective for stool consistency and urgency, though less so for abdominal pain 3.

Practical Implementation

1. Start 75 mg twice daily with food
2. Avoid concurrent use with 1:
   • Other constipating medications (opioids, anticholinergics)
   • Chronic loperamide use (can use occasionally for severe diarrhea but stop if constipation develops)
3. Assess response after 4 weeks - patients who respond in the first month are more likely to have sustained benefit 5
4. Continue monitoring given the elderly patient's higher risk profile

Common Pitfalls to Avoid

• Never prescribe to patients without a gallbladder - this is where most serious adverse events occurred 3, 4
• Don't start at 100 mg in elderly patients - data shows better outcomes with 75 mg in this age group 2
• Don't combine with chronic loperamide - increases constipation risk 1
• Don't overlook alcohol history - even if not meeting "abuse" criteria, >3 drinks/day is a contraindication 3, 1